Myriad’s myPath® Melanoma Test Receives Medicare Coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Needham & Company Reiterates Strong Buy Rating on Myriad Genetics (MYGN) as Final LCD Issued for myPath Melanoma
March 14, 2019 10:46 AM EDTNeedham & Company analyst Stephen Unger reiterated a Strong Buy rating and $41.00 price target on Myriad Genetics (NASDAQ: MYGN) after the company announced the issuance of a final local coverage determination (LCD) for myPath Melanoma under Medicare's MolDx Program.
"This 23-gene test is... More
